Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 7/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100836 | 0.94 | ABL1 (0.43) | ABL1PPARGCNR1SMOPGR | |
| SCHEMBL9104157 | 0.89 | PPARG (0.45) | PPARG | |
| SCHEMBL1099735 | 0.87 | ABL1 (0.44) | ABL1PPARGSMOPGRGPR183 | |
| SCHEMBL1100831 | 0.85 | ABL1 (0.43) | ABL1PPARGCNR1SMOPGR | |
| SCHEMBL1100135 | 0.85 | ABL1 (0.43) | ABL1PPARGCNR1SMOPGR | |
| SCHEMBL1100642 | 0.85 | PPARG (0.44) | PPARGCNR1FLT1KDR | |
| SCHEMBL1100807 | 0.85 | ABL1 (0.43) | ABL1PPARGCNR1SMOPGR | |
| SCHEMBL1100694 | 0.85 | ABL1 (0.43) | ABL1PPARGCNR1SMOPGR | |
| SCHEMBL1100921 | 0.84 | F10 (0.44) | PPARG | |
| Trifluoroacetic Acid SCHEMBL1100621 | 0.83 | ABL1 (0.42) | ABL1PPARGCNR1SMOPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716272-B2 | N-(amino-heteroaryI)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-8716273-B2 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120142669-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142670-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142670-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | ABL1 12/4885PPARG 513/4885CNR1 234/4885 |
| US-20120142669-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | ABL1 12/4885PPARG 513/4885CNR1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.